Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast
Details
Publication Year 2023-01,Volume 82,Issue #1,Page 106-118
Journal Title
Histopathology
Publication Type
Review
Abstract
Ductal carcinoma in situ (DCIS) of the breast is a non-invasive tumour that has the potential to progress to invasive ductal carcinoma (IDC). Thus, it represents a treatment dilemma: alone it does not present a risk to life, however, left untreated it may progress to a life-threatening condition. Current clinico-pathological features cannot accurately predict which patients with DCIS have invasive potential, and therefore clinicians are unable to quantify the risk of progression for an individual patient. This leads to many women being over-treated, while others may not receive sufficient treatment to prevent invasive recurrence. A better understanding of the molecular features of DCIS, both tumour-intrinsic and the microenvironment, could offer the ability to better predict which women need aggressive treatment, and which can avoid therapies carrying significant side-effects and such as radiotherapy. In this review, we summarise the current knowledge of DCIS, and consider future research directions.
Publisher
Wiley
Keywords
Humans; Female; *Carcinoma, Intraductal, Noninfiltrating; Tumor Microenvironment; Dcis; ductal carcinoma in situ; invasive breast cancer; progression; recurrence
Department(s)
Laboratory Research
PubMed ID
36482277
Open Access at Publisher's Site
http://doi.org/10.1111/his.14804
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-15 07:24:50
Last Modified: 2024-07-30 02:13:49

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙